Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Hum Vaccin Immunother
; 19(1): 2206359, 2023 12 31.
Article
in En
| MEDLINE
| ID: mdl-37226504
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Child
/
Humans
Language:
En
Journal:
Hum Vaccin Immunother
Year:
2023
Type:
Article
Affiliation country:
Colombia